Barrington Furr

From SourceWatch
Jump to navigation Jump to search
This article is a stub. You can help by expanding it.

Biographical Information

"Professor Barrington Furr OBE has worked in ICI’s legacy companies Zeneca and AstraZeneca for over 33 years, from which he retired in 2005. In 1997, Professor Furr was appointed Senior Vice-President of Therapeutic Research for Zeneca, a department of over 600 staff in both the UK and US, responsible for drug development in cardiovascular and metabolic diseases, infection cancer and musculoskeletal disease (UK), and neuroscience and respiratory diseases (US).

"Following Zeneca’s merger with Astra in 1999, he was appointed Chief Scientist and Head of Project Evaluation for AstraZeneca Pharmaceuticals and a year later was made head of AstraZeneca’s research centre in Bangalore, which is committed to developing world medicine.

"He is now retired, but consulting within the pharmaceutical industry and is a non-executive director of Genus, the world’s leading livestock genetics company. He is a William Pitt fellow at Pembroke College, Cambridge. During his career Professor Furr has been honoured for his commitment to drug discovery and in 1996, he was awarded the Jubilee Medal of the Society for Endocrinology. He was also made an OBE in the Millennium Honours for services to cancer drug discovery."[1]


Resources and articles

Related Sourcewatch


  1. Medicines and Healthcare products Regulatory Barrington Furr, organizational web page, accessed February 24, 2013.